JingTong Life
closed a tens-of-millions-yuan angel funding round for its aging-reversal research, led by CAS Star (中科创星) and Saizhi Bole, reported across multiple Chinese outlets in 2026.
- Country
- China
Angel-funded
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Partial epigenetic reprogramming | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.